Citations: Honda, Y., Kessoku, T., Sumida, Y
Ipamorelin was developed by Novo Nordisk as a selective GHS-R1a agonist designed to stimulate GH release without significant cortisol or prolactin responses, in contrast to earlier ghrelin-receptor agonists such as GHRP-6 and GHRP-2
Together, these findings underscore that LC's variable clinical efficacy arises from interacting factors including patient phenotype, dosing strategy, intervention duration, and endpoint sensitivity
10.1016/j.surg.2011.08.003 103 KumarS.SaxenaJ.SrivastavaV
A relative of ginger, turmeric roots contain the natural healing compound curcumin
The Ets protein Pointed prevents both premature differentiation and dedifferentiation of Drosophila intermediate neural progenitors